These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37719614)

  • 1. Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis.
    Sreenivasulu H; Muppalla SK; Vuppalapati S; Shokrolahi M; Reddy Pulliahgaru A
    Cureus; 2023 Aug; 15(8):e43603. PubMed ID: 37719614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis.
    Talwalkar JS; Koff JL; Lee HB; Britto CJ; Mulenos AM; Georgiopoulos AM
    Psychosomatics; 2017; 58(4):343-354. PubMed ID: 28576305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.
    Warnock L; Gates A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD001401. PubMed ID: 37042825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of cystic fibrosis care: a global perspective.
    Bell SC; Mall MA; Gutierrez H; Macek M; Madge S; Davies JC; Burgel PR; Tullis E; Castaños C; Castellani C; Byrnes CA; Cathcart F; Chotirmall SH; Cosgriff R; Eichler I; Fajac I; Goss CH; Drevinek P; Farrell PM; Gravelle AM; Havermans T; Mayer-Hamblett N; Kashirskaya N; Kerem E; Mathew JL; McKone EF; Naehrlich L; Nasr SZ; Oates GR; O'Neill C; Pypops U; Raraigh KS; Rowe SM; Southern KW; Sivam S; Stephenson AL; Zampoli M; Ratjen F
    Lancet Respir Med; 2020 Jan; 8(1):65-124. PubMed ID: 31570318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.
    King NE; Suzuki S; Barillà C; Hawkins FJ; Randell SH; Reynolds SD; Stripp BR; Davis BR
    Hum Gene Ther; 2020 Sep; 31(17-18):956-972. PubMed ID: 32741223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Airway clearance devices for cystic fibrosis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(26):1-50. PubMed ID: 23074531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis.
    Lopes-Pacheco M
    Front Pharmacol; 2016; 7():275. PubMed ID: 27656143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic rhinosinusitis in patients with cystic fibrosis-Current management and new treatments.
    Johnson BJ; Choby GW; O'Brien EK
    Laryngoscope Investig Otolaryngol; 2020 Jun; 5(3):368-374. PubMed ID: 32596478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Airway clearance and exercise for people with cystic fibrosis: Balancing longevity with life.
    Rowbotham NJ; Daniels TE
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S50-S59. PubMed ID: 34672434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.
    Saluzzo F; Riberi L; Messore B; Loré NI; Esposito I; Bignamini E; De Rose V
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
    Dawson S; Girling CJ; Cowap L; Clark-Carter D
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis.
    Fajac I; Burgel PR
    Presse Med; 2023 Sep; 52(3):104169. PubMed ID: 37516246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.